The drug-resistant pneumococcus - Clinical relevance, therapy, and prevention

被引:31
作者
Harwell, JI
Brown, RB
机构
[1] Baystate Med Ctr, Div Infect Dis, Springfield, MA 01199 USA
[2] Tufts Univ, Sch Med, Boston, MA 02111 USA
关键词
meningitis; otitis media; pneumococcus; pneumonia; resistance;
D O I
10.1378/chest.117.2.530
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Streptococcus pneumoniae has been known for > 100 years as the most important bacterial pathogen of the respiratory tract in adults and children. In recent years, the pneumococcus has begun to exhibit increasing resistance to antimicrobial agents. Because of the huge number of infections caused by this organism, the development of resistance has changed the approach to many infectious disease problems, particularly with regard to empiric antibiotic therapy and prophylaxis. In our review of the antibiotic-resistant pneumococcus, we review the microbiologic basis for resistance, risk factors for and clinical relevance of infection by a resistant organism, and infection control measures.
引用
收藏
页码:530 / 541
页数:12
相关论文
共 99 条
[1]   Pharmacodynamics of vancomycin for the treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis [J].
Ahmed, A ;
Jafri, H ;
Lutsar, I ;
McCoig, CC ;
Trujillo, M ;
Wubbel, L ;
Shelton, S ;
McCracken, GH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (04) :876-881
[2]   Doxycycline is a cost-effective therapy for hospitalized patients with community-acquired pneumonia [J].
Ailani, RK ;
Agastya, G ;
Ailani, RK ;
Mukunda, BN ;
Shekar, R .
ARCHIVES OF INTERNAL MEDICINE, 1999, 159 (03) :266-270
[3]  
[Anonymous], 1997, MMWR Recomm Rep, V46, P1
[4]   CONFRONTING DRUG-RESISTANT PNEUMOCOCCI [J].
AUSTRIAN, R .
ANNALS OF INTERNAL MEDICINE, 1994, 121 (10) :807-809
[5]   METHICILLIN-RESISTANT STAPHYLOCOCCI [J].
BARBER, M .
JOURNAL OF CLINICAL PATHOLOGY, 1961, 14 (04) :385-&
[6]   COMMUNITY-ACQUIRED PNEUMONIA [J].
BARTLETT, JG ;
MUNDY, LM .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (24) :1618-1624
[7]   Community-acquired pneumonia in adults: Guidelines for management [J].
Bartlett, JG ;
Breiman, RF ;
Mandell, LA ;
File, TM .
CLINICAL INFECTIOUS DISEASES, 1998, 26 (04) :811-838
[8]   Safety and tolerability of a new formulation (90 mg/kg/day divided every 12 h) of amoxicillin/clavulanate (Augmentin®) in the empiric treatment of pediatric acute otitis media caused by drug-resistant Streptococcus pneumoniae [J].
Bottenfield, GW ;
Burch, DJ ;
Hedrick, JA ;
Schaten, R ;
Rowinski, CA ;
Davies, JT .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1998, 17 (10) :963-968
[9]   In-vitro and in-vivo antibacterial activity of quinupristin/dalfopristin [J].
Bouanchaud, DH .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 39 :15-21
[10]   Penicillin dosing for pneumococcal pneumonia [J].
Bryan, CS ;
Talwani, R ;
Stinson, S .
CHEST, 1997, 112 (06) :1657-1664